Information

Secondary changes allow spread of oseltamivir resistant influenza virus

The influenza virus neuraminidase (NA) protein is required for virus release from the cell, a property exploited by the antiviral drugs oseltamivir (Tamiflu) and zanamavir (Relenza). During clinical testing of oseltamivir in 2001, some individuals shed drug-resistant viruses with an amino acid change from histidine to tyrosine (H274Y) in NA. Such viruses are not inhibited …

Secondary changes allow spread of oseltamivir resistant influenza virus Read More »

A new target for hepatitis C virus

When infection with hepatitis C virus goes from acute to chronic, severe liver disease may occur which requires organ transplantation. Nearly 200 million people are chronically infected with HCV, necessitating approaches to preventing and treating infections. No HCV vaccine is available, and current antiviral therapy consists of administration of interferon plus ribavirin, a combination that …

A new target for hepatitis C virus Read More »

XMRV, prostate cancer, and chronic fatigue syndrome

Robert H. Silverman, one of the authors on the study implicating the new human retrovirus XMRV as an etiologic agent of chronic fatigue syndrome, has written an excellent review article on the current status of research on the virus. The article is behind a paywall at Nature Reviews Urology, so I’ll provide a summary of …

XMRV, prostate cancer, and chronic fatigue syndrome Read More »

Scroll to Top